Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366153 | 0.83 | MDM2 (0.52) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366182 | 0.83 | MDM2 (0.56) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366201 | 0.82 | MDM2 (0.50) | MDM2TP53 | |
| SCHEMBL17366183 | 0.80 | MDM2 (0.53) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366148 | 0.80 | CYP2C9 (0.57) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366177 | 0.79 | MEN1 (0.48) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366178 | 0.78 | MDM2 (0.56) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366163 | 0.78 | MDM2 (0.56) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL17366164 | 0.76 | MDM2 (0.53) | MDM2MEN1KMT2APOLBCYP2C9 | |
| SCHEMBL12332978 | 0.76 | MDM2 (0.53) | MDM2MEN1KMT2APOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885MEN1 1807/4885KMT2A 4165/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | MDM2 2/4885MEN1 1807/4885KMT2A 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.